Literature DB >> 32044947

Diagnosis and Treatment of Parkinson Disease: A Review.

Melissa J Armstrong1,2, Michael S Okun1,2.   

Abstract

Importance: Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like movement problems such as rigidity, slowness, and tremor. More than 6 million individuals worldwide have Parkinson disease. Observations: Diagnosis of Parkinson disease is based on history and examination. History can include prodromal features (eg, rapid eye movement sleep behavior disorder, hyposmia, constipation), characteristic movement difficulty (eg, tremor, stiffness, slowness), and psychological or cognitive problems (eg, cognitive decline, depression, anxiety). Examination typically demonstrates bradykinesia with tremor, rigidity, or both. Dopamine transporter single-photon emission computed tomography can improve the accuracy of diagnosis when the presence of parkinsonism is uncertain. Parkinson disease has multiple disease variants with different prognoses. Individuals with a diffuse malignant subtype (9%-16% of individuals with Parkinson disease) have prominent early motor and nonmotor symptoms, poor response to medication, and faster disease progression. Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, a good response to dopaminergic medications (eg, carbidopa-levodopa, dopamine agonists), and slower disease progression. Other individuals have an intermediate subtype. For all patients with Parkinson disease, treatment is symptomatic, focused on improvement in motor (eg, tremor, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs and symptoms. No disease-modifying pharmacologic treatments are available. Dopamine-based therapies typically help initial motor symptoms. Nonmotor symptoms require nondopaminergic approaches (eg, selective serotonin reuptake inhibitors for psychiatric symptoms, cholinesterase inhibitors for cognition). Rehabilitative therapy and exercise complement pharmacologic treatments. Individuals experiencing complications, such as worsening symptoms and functional impairment when a medication dose wears off ("off periods"), medication-resistant tremor, and dyskinesias, benefit from advanced treatments such as therapy with levodopa-carbidopa enteral suspension or deep brain stimulation. Palliative care is part of Parkinson disease management. Conclusions and Relevance: Parkinson disease is a heterogeneous disease with rapidly and slowly progressive forms. Treatment involves pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and nonpharmacologic approaches (such as exercise and physical, occupational, and speech therapies). Approaches such as deep brain stimulation and treatment with levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremor, worsening symptoms when the medication wears off, and dyskinesias.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32044947     DOI: 10.1001/jama.2019.22360

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  276 in total

Review 1.  Expression and function of circular RNAs in the mammalian brain.

Authors:  Kaiyu Xu; Ying Zhang; Jiali Li
Journal:  Cell Mol Life Sci       Date:  2021-02-08       Impact factor: 9.261

2.  Can Quantitative Gait Analysis Be Used to Guide Treatment of Patients with Different Subtypes of Parkinson's Disease?

Authors:  Zhuang Wu; Min Zhong; Xu Jiang; Bo Shen; Jun Zhu; Yang Pan; Jingde Dong; Jun Yan; Pingyi Xu; Wenbin Zhang; Yang Gao; Li Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2020-10-09       Impact factor: 2.570

3.  Safety and Efficacy of Cell Transplantation on Improving Motor Symptoms in Patients With Parkinson's Disease: A Meta-Analysis.

Authors:  Jiaming Wang; Yu Tian; Xin Shi; Zhaohai Feng; Lei Jiang; Yujun Hao
Journal:  Front Hum Neurosci       Date:  2022-05-06       Impact factor: 3.169

4.  Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.

Authors:  Xiumin Liu; Chenkang Wang; Weiwei Liu; Siaoyu Song; Jianing Fu; Toshihiko Hayashi; Kazunori Mizuno; Shunji Hattori; Hitomi Fujisaki; Takashi Ikejima
Journal:  Neurochem Res       Date:  2021-06-07       Impact factor: 3.996

5.  High-quality nursing intervention can improve negative emotions, quality of life and activity of daily living of elderly patients with Parkinson's disease.

Authors:  Yihui Gui; Youya Zhou
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 6.  Diagnosis and Management of Pain in Parkinson's Disease: A New Approach.

Authors:  Veit Mylius; Jens Carsten Möller; Stephan Bohlhalter; Daniel Ciampi de Andrade; Santiago Perez Lloret
Journal:  Drugs Aging       Date:  2021-07-05       Impact factor: 3.923

Review 7.  Autonomic Dysfunction in Parkinson's Disease.

Authors:  Ronald F Pfeiffer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

8.  A Parkinson's Disease-relevant Mitochondrial and Neuronal Morphology High-throughput Screening Assay in LUHMES Cells.

Authors:  Tom Leah; Irina Vazquez-Villaseñor; Laura Ferraiuolo; Stephen B Wharton; Heather Mortiboys
Journal:  Bio Protoc       Date:  2021-01-05

9.  Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.

Authors:  Joe Yamamoto; Tomohiro Omura; Sachiko Kasamo; Shota Yamamoto; Masayoshi Kawata; Atsushi Yonezawa; Yosuke Taruno; Hisako Endo; Hitoshi Aizawa; Nobukatsu Sawamoto; Kazuo Matsubara; Ryosuke Takahashi; Yoshikazu Tasaki
Journal:  J Neural Transm (Vienna)       Date:  2020-11-02       Impact factor: 3.575

10.  Icariside II promotes the differentiation of human amniotic mesenchymal stem cells into dopaminergic neuron-like cells.

Authors:  Wei Kuang; Tao Liu; Fang He; Limei Yu; Qian Wang; Changyin Yu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-03-15       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.